362 related articles for article (PubMed ID: 31018854)
1. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Mei L; Zhang J; He K; Zhang J
J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
[TBL] [Abstract][Full Text] [Related]
2. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
3. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K
Cells; 2020 Jan; 9(1):. PubMed ID: 31963582
[TBL] [Abstract][Full Text] [Related]
4. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
6. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
Edwards TG; Bloom DC; Fisher C
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
[TBL] [Abstract][Full Text] [Related]
7. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Bradbury A; Hall S; Curtin N; Drew Y
Pharmacol Ther; 2020 Mar; 207():107450. PubMed ID: 31836456
[TBL] [Abstract][Full Text] [Related]
8. ATR Inhibition in Advanced Urothelial Carcinoma.
Leibrandt RC; Tu MJ; Yu AM; Lara PN; Parikh M
Clin Genitourin Cancer; 2023 Apr; 21(2):203-207. PubMed ID: 36604210
[TBL] [Abstract][Full Text] [Related]
9. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Manavella DD; McNamara B; Harold J; Bellone S; Hartwich TMP; Yang-Hartwich Y; Mutlu L; Zipponi M; Demirkiran C; Verzosa MS; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Dottino PR; Choi J; Alexandrov LB; Buza N; Hui P; Santin AD
Gynecol Oncol; 2023 Feb; 169():98-105. PubMed ID: 36525930
[TBL] [Abstract][Full Text] [Related]
10. ATR-Chk1 activation mitigates replication stress caused by mismatch repair-dependent processing of DNA damage.
Gupta D; Lin B; Cowan A; Heinen CD
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1523-1528. PubMed ID: 29378956
[TBL] [Abstract][Full Text] [Related]
11. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
12. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
13. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
14. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
15. Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells.
Zhang S; Zhao Y; Wang X; Qi C; Tian J; Zou Z
Life Sci; 2023 Nov; 332():122131. PubMed ID: 37778414
[TBL] [Abstract][Full Text] [Related]
16. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
J Virol; 2019 May; 93(9):. PubMed ID: 30787154
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
Biskup E; Naym DG; Gniadecki R
J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
[TBL] [Abstract][Full Text] [Related]
18. Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin.
Hahm ER; Lee J; Abella T; Singh SV
Mol Carcinog; 2019 Nov; 58(11):2139-2148. PubMed ID: 31441116
[TBL] [Abstract][Full Text] [Related]
19. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase.
Alfayomy AM; Ashry R; Kansy AG; Sarnow AC; Erdmann F; Schmidt M; Krämer OH; Sippl W
Eur J Med Chem; 2024 Mar; 267():116167. PubMed ID: 38308949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
